Passage BIO Inc

For the period ended Sep 30, 2024. Filed Nov 13, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 13, 2024

PASG$3.43-13.7%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Statements of Operations and Comprehensive Loss


· · Three Months Ended September 30, · · Nine Months Ended September 30,
(in thousands, except share and per share data) · 2024 · 2023 · · 2024 · 2023
Operating expenses: · · · · ·
Research and development	$8,656	$15,098	$30,621	$49,258
General and administrative	7,251	8,184	20,276	35,295
Impairment of long-lived assets	4,795	5,390	5,233	5,390
Loss from operations	(20,702)	(28,672)	(56,130)	(89,943)
Other income (expense), net	1,362	1,562	4,088	4,639
Net loss	$(19,340)	$(27,110)	$(52,042)	$(85,304)
Per share information:
Net loss per share of common stock, basic and diluted	$(0.31)	$(0.49)	$(0.87)	$(1.56)
Weighted average common shares outstanding, basic and diluted	61,763,346	54,789,410	59,920,537	54,697,967
Comprehensive loss:
Net loss	$(19,340)	$(27,110)	$(52,042)	$(85,304)
Unrealized gain (loss) on marketable securities	99	148	75	774
Comprehensive loss	$(19,241)	$(26,962)	$(51,967)	$(84,530)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.